Ironwood Pharmaceuticals Inc
Company Profile
Business description
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Contact
100 Summer Street
Suite 2300
BostonMA02110
USAT: +1 617 621-7722
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
267
Stocks News & Analysis
stocks
Signs of a turnaround for undervalued ASX share
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,825.10 | 20.90 | 0.24% |
| CAC 40 | 8,178.54 | 14.43 | 0.18% |
| DAX 40 | 22,513.42 | 98.60 | -0.44% |
| Dow JONES (US) | 44,579.30 | 132.13 | -0.30% |
| FTSE 100 | 8,732.46 | 32.26 | -0.37% |
| HKSE | 22,620.33 | 805.96 | 3.69% |
| NASDAQ | 19,944.56 | 1.08 | -0.01% |
| Nikkei 225 | 39,149.43 | 312.04 | -0.79% |
| NZX 50 Index | 12,989.18 | 83.20 | 0.64% |
| S&P 500 | 6,109.29 | 5.78 | -0.09% |
| S&P/ASX 200 | 8,555.80 | 15.80 | 0.19% |
| SSE Composite Index | 3,346.72 | 14.24 | 0.43% |